TR201807912T4 - Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇. - Google Patents
Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇.Info
- Publication number
- TR201807912T4 TR201807912T4 TR2018/07912T TR201807912T TR201807912T4 TR 201807912 T4 TR201807912 T4 TR 201807912T4 TR 2018/07912 T TR2018/07912 T TR 2018/07912T TR 201807912 T TR201807912 T TR 201807912T TR 201807912 T4 TR201807912 T4 TR 201807912T4
- Authority
- TR
- Turkey
- Prior art keywords
- synthesis methods
- phosphate receptor
- chiral synthesis
- receptor regulators
- regulators
- Prior art date
Links
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 108091006073 receptor regulators Proteins 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26130109P | 2009-11-13 | 2009-11-13 | |
| US26247409P | 2009-11-18 | 2009-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201807912T4 true TR201807912T4 (tr) | 2018-06-21 |
Family
ID=43992106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/07912T TR201807912T4 (tr) | 2009-11-13 | 2010-11-15 | Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇. |
Country Status (32)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2498611T (pt) | 2009-11-13 | 2018-04-13 | Celgene Int Ii Sarl | Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral |
| CA2780772C (en) | 2009-11-13 | 2018-01-16 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| ES2758841T3 (es) | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
| SMT201700287T1 (it) * | 2012-06-21 | 2017-07-18 | Eisai R&D Man Co Ltd | Nuovo derivato di indansolfammide |
| WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
| EP3062792A1 (en) * | 2013-11-01 | 2016-09-07 | Celgene International II Sarl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| CA2981743A1 (en) | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| ES3022204T3 (en) | 2016-06-14 | 2025-05-28 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| JP6883882B2 (ja) * | 2016-07-22 | 2021-06-09 | シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド | Ｓ１ｐ１アゴニスト及びその応用 |
| US11028060B2 (en) | 2016-08-19 | 2021-06-08 | Receptos Llc | Crystalline forms of ozanimod and processes for preparation thereof |
| WO2018050091A1 (zh) | 2016-09-14 | 2018-03-22 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| CN108137516A (zh) * | 2016-09-14 | 2018-06-08 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
| JP7086945B2 (ja) | 2016-09-29 | 2022-06-20 | レセプトス・リミテッド・ライアビリティ・カンパニー | 狼瘡を処置するための化合物および方法 |
| JP7123956B2 (ja) * | 2017-02-28 | 2022-08-23 | ヘリオイースト・ファーマシューティカル・カンパニー・リミテッド | スピロ化合物およびその使用 |
| US20200031784A1 (en) * | 2017-04-07 | 2020-01-30 | Solipharma Llc | Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses |
| CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
| CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
| EP3621610A1 (en) | 2017-05-08 | 2020-03-18 | Celgene International II Sàrl | Sphingosine 1 phosphate receptor agonists for neuroprotection |
| MA48798B1 (fr) * | 2017-05-22 | 2023-10-31 | Egyt Gyogyszervegyeszeti Gyar | Procédé de production d'ozanimod |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10675255B2 (en) | 2017-06-23 | 2020-06-09 | Enzo Bochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
| EP3677575A4 (en) | 2017-08-31 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR |
| WO2019058290A1 (en) * | 2017-09-20 | 2019-03-28 | Suven Life Sciences Limited | IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| CN107857760A (zh) * | 2017-11-21 | 2018-03-30 | 南京天翔医药科技有限公司 | 鞘氨醇‑1‑磷酸受体调节剂及其应用 |
| BR112020014488A2 (pt) * | 2018-01-18 | 2020-12-01 | Shijiazhuang Sagacity New Drug Development Company, Ltd. | formas cristalinas e salinas do composto tricíclico e processo de preparação das mesmas |
| CA3092295A1 (en) | 2018-03-20 | 2019-09-26 | Eisai R&D Management Co., Ltd. | Epilepsy treatment agent |
| CN110615747A (zh) * | 2018-06-20 | 2019-12-27 | 广东东阳光药业有限公司 | 一种二氢茚中间体的制备方法 |
| CA3124986A1 (en) | 2018-06-25 | 2020-01-02 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| EP3849965A1 (en) | 2018-09-12 | 2021-07-21 | Pharmazell GmbH | A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| MX2021006692A (es) * | 2018-12-07 | 2021-07-07 | Synthon Bv | Proceso mejorado para preparar ozanimod. |
| CN113891883A (zh) * | 2019-03-29 | 2022-01-04 | 瑞塞普托斯公司 | 1-磷酸鞘氨醇受体调节剂 |
| EP3947362A4 (en) * | 2019-03-29 | 2023-01-04 | Receptos Llc | SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS |
| WO2020205483A1 (en) * | 2019-03-29 | 2020-10-08 | Celgene International Ii Sarl | Sphingosine 1 phosphate receptor modulators |
| US20220227722A1 (en) * | 2019-04-26 | 2022-07-21 | Receptos Llc | Sphingosine 1 phosphate receptor modulator |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| EP3999495A1 (en) | 2019-07-16 | 2022-05-25 | Synthon B.V. | Improved process for preparing ozanimod |
| CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| TW202135804A (zh) * | 2020-01-06 | 2021-10-01 | 美商艾尼納製藥公司 | 治療與s1p1受體相關之病況的方法 |
| EP4116295A4 (en) * | 2020-03-04 | 2023-08-02 | Helioeast Pharmaceutical Co., Ltd. | TRICYCLIC COMPOUNDS AND THEIR USE |
| CN115279740B (zh) * | 2020-03-04 | 2025-02-28 | 南昌弘益药业有限公司 | 苯并2-氮杂螺[4.4]壬烷类化合物及其应用 |
| EP4121025A4 (en) * | 2020-03-17 | 2024-03-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of coronavirus infection |
| JP2023518968A (ja) * | 2020-03-27 | 2023-05-09 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１ホスフェート受容体モジュレーター |
| US12364686B2 (en) | 2020-03-27 | 2025-07-22 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| EP4126826A1 (en) | 2020-04-02 | 2023-02-08 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| CN111620788B (zh) * | 2020-04-20 | 2022-09-30 | 广东莱佛士制药技术有限公司 | 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
| WO2022213935A1 (zh) * | 2021-04-09 | 2022-10-13 | 南昌弘益药业有限公司 | 噁二唑取代的螺环类化合物及其应用 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| WO2024246174A1 (en) | 2023-05-31 | 2024-12-05 | Química Sintética, S.A. | Amorphous and crystalline form of ozanimod hydrochloride |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
| CN119462405B (zh) * | 2025-01-10 | 2025-05-27 | 天津阿尔塔科技有限公司 | 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) * | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| AU1886892A (en) | 1991-04-12 | 1992-11-17 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| CA2318361A1 (en) * | 1998-01-23 | 1999-07-29 | Sankyo Company Limited | Spiropiperidine derivatives |
| AR035585A1 (es) † | 2000-09-15 | 2004-06-16 | Pharmacia Corp | Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| EP1581509B1 (en) | 2002-12-20 | 2011-01-19 | Merck Sharp & Dohme Corp. | 1-(amino)indanes as edg receptor agonists |
| DK3549936T3 (da) | 2003-04-11 | 2021-07-12 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom |
| EP1670463A2 (en) | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| CN1894225A (zh) * | 2003-12-17 | 2007-01-10 | 默克公司 | 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯 |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CA2600008A1 (en) | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| BRPI0614090A2 (pt) † | 2005-08-03 | 2011-03-09 | Novartis Ag | uso de inibidores da hdac para o tratamento do mieloma |
| AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| PE20070705A1 (es) * | 2005-11-25 | 2007-08-23 | Basf Ag | Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales |
| JP5514443B2 (ja) | 2005-12-21 | 2014-06-04 | ジョセフ ガブリエル， | カテコールアミン調節性タンパク質 |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| US20080009534A1 (en) | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| JP5250556B2 (ja) * | 2006-09-21 | 2013-07-31 | アクテリオン ファーマシューティカルズ リミテッド | フェニル誘導体及びそれらの免疫調節薬としての使用 |
| WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| WO2008143730A2 (en) | 2007-02-28 | 2008-11-27 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| GB0725104D0 (en) † | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| WO2009131090A1 (ja) | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
| PL2291080T3 (pl) * | 2008-05-14 | 2015-12-31 | Scripps Research Inst | Nowe modulatory receptorów sfingozyno-1-fosforanu |
| CN102066752B (zh) * | 2008-06-13 | 2014-02-19 | (学)斗源学院 | 具有回转阀的往复式压缩机 |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
| DK2498609T3 (en) | 2009-11-13 | 2018-06-18 | Celgene Int Ii Sarl | SELECTIVE HETEROCYCLIC SPHINGOSIN-1 PHOSPHATRECEPTOR MODULATORS |
| CA2780772C (en) | 2009-11-13 | 2018-01-16 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| PT2498611T (pt) | 2009-11-13 | 2018-04-13 | Celgene Int Ii Sarl | Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral |
| ES2758841T3 (es) | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2010
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
- 2010-11-15 PT PT181606674T patent/PT3406142T/pt unknown
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 RS RS20180647A patent/RS57253B2/sr unknown
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/ko active Active
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/es active IP Right Grant
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/tr unknown
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/ja active Active
- 2010-11-15 SM SM20180288T patent/SMT201800288T1/it unknown
- 2010-11-15 HR HRP20180874TT patent/HRP20180874T4/hr unknown
- 2010-11-15 PL PL18160667T patent/PL3406142T3/pl unknown
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/hu unknown
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/lt unknown
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 ES ES10830880T patent/ES2673160T5/es active Active
- 2010-11-15 PL PL10830880.0T patent/PL2498610T5/pl unknown
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/ko active Active
- 2010-11-15 SI SI201032063T patent/SI3406142T1/sl unknown
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/da active
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/pt active IP Right Grant
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 PH PH1/2012/500939A patent/PH12012500939A1/en unknown
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 PT PT108308800T patent/PT2498610T/pt unknown
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en not_active Ceased
- 2010-11-15 ES ES18160667T patent/ES2858337T3/es active Active
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/zh active Active
- 2010-11-15 EA EA201690391A patent/EA035768B1/ru not_active IP Right Cessation
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/pt active IP Right Grant
- 2010-11-15 EA EA201290323A patent/EA024801B1/ru not_active IP Right Cessation
- 2010-11-15 DK DK10830880.0T patent/DK2498610T4/da active
- 2010-11-15 EP EP10830880.0A patent/EP2498610B2/en active Active
- 2010-11-15 SI SI201031704T patent/SI2498610T2/sl unknown
- 2010-11-15 SM SM20210169T patent/SMT202100169T1/it unknown
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/zh active Active
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/hu unknown
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/lt unknown
- 2010-11-15 RS RS20210360A patent/RS61829B1/sr unknown
-
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/ja active Active
-
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/ja active Pending
-
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708B1/en unknown
-
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
-
2018
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/el unknown
-
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
-
2020
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/hu unknown
- 2020-11-18 NO NO2020039C patent/NO2020039I1/no unknown
- 2020-11-18 LU LU00184C patent/LUC00184I2/en unknown
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/lt unknown
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/fr active Active
- 2020-11-19 CY CY2020035C patent/CY2020035I2/el unknown
-
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/hr unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/el unknown
-
2024
- 2024-02-29 FI FIEP10830880.0T patent/FI2498610T4/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201807912T4 (tr) | Seçi̇ci̇ sfi̇ngozi̇n 1 fosfat reseptör düzenleyi̇ci̇leri̇ ve ki̇ral sentez yöntemleri̇. | |
| CY1125421T1 (el) | Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων | |
| BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
| EA201200507A1 (ru) | Применение активаторов никотинового ацетилхолинового рецептора альфа 7 | |
| ZA201209381B (en) | The use of inhibitors of bruton's tyrosine kinase (btk) | |
| BR112012022513A2 (pt) | derivados de piperidin-4-il azetidina como inibidores de jak1 | |
| TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
| BR112014027165A2 (pt) | antagonistas de st2l e métodos de uso | |
| JO3450B1 (ar) | أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز | |
| EA201291180A1 (ru) | Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6) | |
| DE602007012072D1 (de) | Orantagonisten | |
| EP2529355A4 (en) | VOICE BODY IDENTITY CORRELATION | |
| BR112012020273A2 (pt) | Compostos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno e pirazolotiazol como pontencializadores alostéricos de mglur4, composições e métodos de tratamento de disfunção neurológica | |
| EP2498609A4 (en) | SELECTIVE HETEROCYCLIC SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS | |
| MX348451B (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12. | |
| EA201270280A1 (ru) | Соединения пиримидина в качестве ингибиторов при лечении туберкулеза | |
| IL206359A0 (en) | Sulfonamides as orexin antagonists | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
| JO2682B1 (en) | Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof | |
| BRPI1013777A8 (pt) | Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos. | |
| MX379538B (es) | Moduladores novedosos de receptores de fosfato de esfingosina. | |
| BR112014007451A2 (pt) | síntese in vivo de fibras elásticas | |
| CR20120502A (es) | Uso de nuevos inhibidores de pan-cdk para tratar tumores | |
| BR112015008389A2 (pt) | compostos úteis na síntese de compostos de benzamida |